Conflicts seen on guidelines panel

The AHA/ACC panel that wrote the potentially practice-changing cholesterol guidelines issued last month included six members with ties to drugmakers that sell or are developing lipid medications, Pharmalot reported. Each disclosed they worked as a consultant and received funding for personal research.

Among the 10 expert reviewers, half listed consulting relationships with such companies cited as Merck, Amgen, AstraZeneca, Pfizer, Amarin, Roche and Abbott Laboratories, whose cholesterol pills are sold by AbbVie. An AHA spokeswoman responded that none of the ACC/AHA expert reviewers had “relevant” relationships with industry.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.